Eptacog alfa pegol (activated)

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Eptacog alfa pegol (activated)
Accession Number
DB11661
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Blood factors
Description

Eptacog alfa pegol (activated) has been used in trials studying the prevention and treatment of Haemophilia A, Haemophilia B, Congenital Bleeding Disorder, Haemophilia B With Inhibitors, and Haemophilia A With Inhibitors.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
  • Activated Recombinant Human Factor VII, Long Acting
Categories
UNII
3Q26I70P3I
CAS number
944130-77-2

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Abicipar PegolThe therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Eptacog alfa pegol (activated).
Antihemophilic Factor (Recombinant), PEGylatedThe therapeutic efficacy of Eptacog alfa pegol (activated) can be decreased when used in combination with Antihemophilic Factor (Recombinant), PEGylated.
Cepeginterferon alfa-2BThe therapeutic efficacy of Cepeginterferon alfa-2B can be decreased when used in combination with Eptacog alfa pegol (activated).
Certolizumab pegolThe therapeutic efficacy of Eptacog alfa pegol (activated) can be decreased when used in combination with Certolizumab pegol.
Damoctocog alfa pegolThe therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Eptacog alfa pegol (activated).
Egaptivon pegolThe therapeutic efficacy of Eptacog alfa pegol (activated) can be decreased when used in combination with Egaptivon pegol.
ElapegademaseThe therapeutic efficacy of Elapegademase can be decreased when used in combination with Eptacog alfa pegol (activated).
GlycoPEG-GCSFThe therapeutic efficacy of Eptacog alfa pegol (activated) can be decreased when used in combination with GlycoPEG-GCSF.
Heptaethylene glycolThe therapeutic efficacy of Eptacog alfa pegol (activated) can be decreased when used in combination with Heptaethylene glycol.
Insulin peglisproThe therapeutic efficacy of Eptacog alfa pegol (activated) can be decreased when used in combination with Insulin peglispro.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911224

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentCongenital Hematological Disorder / Haemophilia B / Healthy Volunteers / Hemophilia A1
1CompletedTreatmentCongenital Hematological Disorder / Haemophilia B / Hemophilia A1
2CompletedPreventionCongenital Hematological Disorder / Haemophilia A With Inhibitors / Haemophilia B With Inhibitors1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 14:38 / Updated on February 06, 2020 13:11